From vaccines and pharmaceuticals, to biofuels, food and household goods, developments in bioprocessing and biotechnology have the potential to significantly influence the future of manufacturing, medicine and energy. Significant challenges remain in many areas, such as complex regulatory issues and the ever-present need to improve productivity and consistency, whilst reducing costs, resulting in the generation of highly valuable and eminently protectable innovation for our clients.
Progress in bioprocessing within the pharmaceutical sector is motivated by a growing demand for novel therapeutics, including biopharmaceutical medicines and vaccines, and the rapid emergence of disruptive cell and gene therapy treatments.
In the energy sector, research and development is spurred by public desire and government support for more efficient, cleaner systems that enable a shift away from traditional petrochemicals.
And in food and nutrition, growing demands for meat replacements, increased shelf life, enhanced quality and health-promoting products are all influencing a range of technological developments.
These, and other areas of bioprocessing and biotechnology, are underpinned by a plethora of technologies, from vector design to process control, fermenter engineering to product recovery. HGF has been at the cutting-edge of developments in bioprocessing and biotechnology for many years, with a specialist team combining comprehensive scientific knowledge and commercial understanding to develop and implement legally and commercially astute IP strategies. Working with a wide range of clients, from global pharmaceutical and biotech companies, to SMEs and universities, the team supports innovation across all sectors.
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches’. Selecting the right trade mark for your new healthcare product is a critically important task. Consumers …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
World Intellectual Property Day is on 26th April. This year’s theme is IP & SME’s: Taking your ideas to market. World IP day 2021 shines a light on the critical role of …Event details
‘IP & data protection for alternative proteins: how to protect your products in the EU’ webinar will be held on Tuesday 18th May. Join this webinar by BGP, HGF & …Event details